Encapsulate

Encapsulate, a developer of personalized oncology solutions, has raised $1.8 million in seed funding, led by Blackwood Healthcare Breakthroughs, Ambit Health Ventures, and Connecticut Innovations. Encapsulate’s technology transforms a tiny slice of a patient’s tumor tissue into many microtumors, then conducts different tests on each microtumor. Encapsulate’s platform can provide individualized treatment recommendations in as few as seven days. “While many companies work on personalized cancer treatments, Encapsulate validates its recommendations on a patient’s own tumor cells,” said Chris Willenken, Partner at Blackwood Healthcare Breakthroughs. “This evidence-based approach improves accuracy and reduces risk.” Read the full press release: https://lnkd.in/eWzAv2Fb #medtech #personalizedoncology #science #diagnostics #deeptech #spacetech #PrecisionMedicine #CancerTech #VentureCapital

We are thrilled to announce that Encapsulate has secured 2nd place and a $75,000 cash prize at the 2024 Entrepreneurship World Cup Global Finals! Competing among the top 100 startups from 52 countries, Encapsulate was recognized for our advanced tumor-on-a-chip system that personalizes chemotherapy selection. Our innovative technology delivers rapid, evidence-based insights, enabling oncologists to identify the most effective treatments and significantly improve patient outcomes. This recognition reinforces our commitment to revolutionizing cancer therapy through precision diagnostics and personalized treatment strategies. We are deeply grateful to the organizers, judges, and supporters who made this achievement possible, and to our Co-Founder and COO, Leila Daneshmandi, PhD, who represented Encapsulate on the global stage at BibanGlobal. The Entrepreneurship World Cup, co-hosted by the Global Entrepreneurship Network and Saudi Arabia’s Small and Medium Enterprises General Authority, MonshaatSA, is one of the largest and most diverse pitch competitions globally. The top 100 finalists, selected from 16,000 startups across 200+ countries, were invited to pitch at the 2024 Global Finals following rigorous national and regional qualifiers, global pool selections, and a bootcamp for the top 250 companies. We are excited to continue pushing the boundaries of cancer treatment innovation and are honored to have been recognized among the world’s leading startups. #EntrepreneurshipWorldCup #EWC2024 #HealthcareInnovation #CancerTherapy #PrecisionMedicine #Encapsulate

Next week, we're thrilled to be presenting at the ISSRDC conference in Boston with our groundbreaking study: "Encapsulate: Automated Biochips for Personalized Cancer Screening in Microgravity". For the first time, we'll be sharing the incredible data achieved from our research on the International Space Station, as part of the SpaceX CRS-30 mission. This study represents the effects of microgravity on patient responses to a variety of chemodrugs, and is a huge leap forward in personalized cancer therapy, utilizing microgravity to enhance our automated biochips' capabilities. Join us as we explore how microgravity can revolutionize cancer screening and treatment, pushing the boundaries of what's possible in space and medicine. #ISSRDC2024 #CancerResearch #SpaceMedicine #Microgravity

Encapsulate is honored to have received Senator Chris Murphy's "Innovator of the Month" recognition for its transformative contributions in advancing cancer precision diagnostics and treatment. Read the full press release: https://lnkd.in/ec22i8xD

What a day for Encapsulate and our team! Yesterday marked a pivotal moment as we witnessed the launch of our cargo destined for the International Space Station, advancing our mission in cancer therapy. On Thursday, March 21 at 4:55 p.m. ET, Falcon 9 launched Dragon’s CRS-30 to the International Space Station National Laboratory from Cape Canaveral Space Force Station in Florida, carrying with it our cargo of cancer patients' samples and our technology, now en route to the International Space Station. Space exploration transcends venturing into the unknown; it embodies our commitment to innovation in confronting humanity's most daunting challenges, including cancer. At the heart of our mission lies the pursuit to understand the effects of microgravity on cancer. The insights we gain from this mission have the potential to revolutionize our understanding of this complex disease, in ways previously unexplored, and significantly impact treatment processes on Earth, opening doors to limitless possibilities. There are countless individuals and organizations who have supported us, from MassChallenge Boston where it all began, to esteemed partners, including the International Space Station National Laboratory, Boeing, Space Tango, NASA - National Aeronautics and Space Administration, SpaceX, and the University of Connecticut. Our deepest appreciation goes to the individuals who have lent their support and expertise to our work over the years: Jennifer Read, GMPro™ QAPro™, John Catechis, Joel Levine, Bret Schipper, MD, FACS, CPE, Rawad Elias, Sven Eenmaa, Nicole Wagner, Ph.D., Scott Copeland, Kevin D. Foley, Rachel Clemens, PhD, Davide Marotta, Ph.D., and in loving memory of Etop Esen whose initial encouragement inspired our pursuit. We must recognize the tireless efforts of our team and Space Tango, including, Taylor S., Kendall Nelson, Mark Reeves, Zach Jacobs, Twyman Clements, Alain Berinstain, Benjamin Lumpp, Isabel Moore, Paul Gamble, PMP, Trevor Nienaber, Shelby Giza, and Anne Currin. Read more about our mission in the official press release from the ISSNL: https://lnkd.in/eM7ey5Ws Watch the launch stream from the Kennedy Space Center here: https://lnkd.in/gTjA6ReB The journey ahead is bound to be exciting, and with the collective efforts of our team and the support of our partners, we are poised to make profound strides in the fight against cancer. Together, we are rewriting the narrative of possibility, one launch at a time. 💫 🔬 #Encapsulate #CancerTherapy #Cancer #Innovation #SpaceResearch #NASA #SpaceX #InternationalSpaceStation